Tag Archives: Eleven Biotherapeutics

September, 2016

21 September
Eleven Biotherapeutics Acquires Viventia Bio Creating Targeted Protein Therapeutics Oncology Company

CAMBRIDGE, Mass. & TORONTO–(BUSINESS WIRE)–Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) and Viventia Bio Inc., today announced that the two companies and the shareholders of Viventia entered into a definitive share purchase agreement under which Eleven Biotherapeutics agreed to, and simultaneously completed, the acquisition of Viventia. Under the agreement, Eleven purchased all …
Share

15 June
Roche to License Eleven Bio’s IL-6 Antagonist Antibody Technology in $270 Million Deal

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that it has entered into an exclusive license agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche) relating to Eleven’s Interleukin-6 (IL-6) technology. Under the terms of …
Share